Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 26 ... acquires the use of 3M's patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M's TLR agonists could enhance vaccine potency, ... increasing the effectiveness of vaccines," said Dr. Mark Tomai, PhD, Vaccine Business Development Director, 3M Drug Delivery Systems."The combination of VaxInnate's ...
2009 NOV 29 ... malaria because different tactics will work in different scenarios. In some places, a vaccine may work best, in more remote places, other low cost, low tech approaches will work ... that triggers an immune response in multiple mosquito species capable of stopping the development of Plasmodium falciparum. By silencing the gene, caspar, the researchers were able to ...
2009 NOV 24 ... Acute Gastroenteritis, Vaccination, Immunization, Gastroenterology, Rotavirus Vaccine, Polymerase, Enzymes, Diagnosis, Diagnostics, Immunoassay. This article was ... colleagues. The researchers concluded: "These data highlight the need for development and implementation of effective prophylactic measures, such as vaccines, to prevent the ...
2009 NOV 25 ... Officer of Novavax, stated: "We are continuing to make rapid progress with each of our vaccine development programs which are targeting some of the world's most pressing public health problems. ...
2009 NOV 24 ... Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced that John Trizzino, Senior Vice President, International and ... America addressing every aspect of influenza policy and planning, influenza research, development and stakeholder partnerships. The influenza vaccine is the fastest growing segment in ...
2009 NOV 29 ... vaccination rates varied widely across individual physicians (11-98 percent for PPV vaccine and 22-96 percent for influenza vaccine). They also found that longer reported ... and family medicine residency. They conclude that a successful partnership relies on the development of a shared mission of education and service, as well as innovation and flexibility by ...
2009 NOV 23 ... of activities related to RypVax™ and the Company's third generation rPA anthrax vaccine program. General and administrative expenses were $6.2 million and $4.8 ... Revenues consisted primarily of contract funding from the U.S. government for the development of SparVax™, Valortim=AE and Protexia=AE. Research and development ...
2009 NOV 24 ... companies from more than 15 cities throughout China and also operates a vaccine research center and biometrics center, which will bolster PPD's global expertise in ... research organizations in China. The acquisition strengthens PPD's full range of drug development services in the country and positions it to capitalize on the tremendous growth of the ...
2009 NOV 23 ... vaccinated during child-bearing years, including vaccination with BioThrax (Anthrax Vaccine Adsorbed, or AVA). As only a limited number of studies exist in humans that have ... organogenesis. Blood samples were collected from does and fetuses/kits to assess the development and in utero transfer of antibodies to Bacillus anthracis protective antigen (anti-PA ...
2009 NOV 23 ... WSSV. The result showed that the groups treated with IgY from inactivated WSSV and DNA vaccine were, respectively, 20% and 80% mortality, which were significant difference in survival ... that the passive immunization of crayfish with IgY against WSSV will have potential development to prevent and control WSSV in practical culture." Lu and colleagues ...
2009 NOV 23 ... objective of this study was to demonstrate the efficacy of a modified-live virus (MLV) vaccine in protecting fetuses from infection with type 1 or type 2 Bovine viral diarrhea virus ... contact W.Z. Xue, Intervet Schering Plough Animal Health, Biology Research & Development, 35500 W 91st St., De Soto, KS 66018, USA.The publisher of the Canadian ...
2009 NOV 24 ... respect to the immunotyping scheme for the meningococci and in the context of LPS-based vaccine development." St and colleagues published their study in Glycobiology ...
2009 NOV 23 ... Options for the prevention or therapy of HCV infection are limited; there is no vaccine and the nonspecific, interferon-based treatments now in use are frequently ineffective ... "A small-animal model for HCV infection would significantly expedite antiviral compound development and preclinical testing, as well as open new avenues to decipher the mechanisms that ...
2009 NOV 23 ... proteins involved in the immune response to hCMV has emerged as a major focus of hCMV vaccine research." "Validation of the protective effect of DNA vaccination in ... vaccination in animal models has provided support for clinical trials. VCL-CB01, under development byVical Inc for the prevention of hCMV infection and disease, is a poloxamer-formulated, ...
2009 NOV 24 ... of additional ETEC surface molecules suggests that new targets may be exploited in vaccine development. The EtpA protein identified in ETEC H10407 is a large glycosylated adhesin secreted via ...
2009 NOV 23 ... and cellular immunology have paved the way toward the rational design of an efficacious vaccine. We exploited self-cleaving peptide 2A from the foot-and-mouth disease virus, because of ... concluded: "These results have important implications for the rational design and development of efficacious recombinant subunit vaccines." Mir and colleagues published ...
2009 NOV 23 ... for vaccination of German children <2 years with the pneumococcal conjugate vaccine was issued at the end of July 2006," investigators in Aachen, Germany report. ... seven-valent conjugate vaccine was 43.9%. For the ten-valent and 13-valent vaccines (in development), the coverages were 61.8% and 76.7%, respectively," wrote M. Imohl and colleagues, ...
2009 NOV 23 ... pathology and the development of EP," scientists writing in the journal Clinical and Vaccine Immunology report. "Blood and fallopian tubes were collected from 14 women ...
2009 NOV 23 ... after the administration of CIGB-230 in mice, as well as toxicity of this vaccine candidate in rats." "In the biodistribution study, mice received single ... Keywords: City:Havana, Country:Cuba, Biotechnology, DNA Research, DNA Vaccines, Drug Development, Gastroenterology, HCV, Hepatitis C Virus, Hepatology, Immunization, Infectious Disease, ...
2009 NOV 23 ... rapid growth based upon more market awareness after the introduction of the HPV vaccine, Gardasil®, which was developed by Merck & Co. (NYSE: MRK). The ... market offers our business a large market opportunity and is one of our leading product development priorities. Our plan is to develop a wide range of tests that utilize our patented ...
